Parathyroid cancer overview

Jump to navigation Jump to search

Parathyroid cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Parathyroid cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Parathyroid cancer overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Parathyroid cancer overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Parathyroid cancer overview

CDC on Parathyroid cancer overview

Parathyroid cancer overview in the news

Blogs on Parathyroid cancer overview

Directions to Hospitals Treating Type chapter name here

Risk calculators and risk factors for Parathyroid cancer overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Parathyroid cancer was first described by Sainton and Millot, in 1933. In 1928, the first parathyroidectomy operation was conducted by Isaac Y. Olch to treat parathyroid lesions. On gross pathology, stony-hard consistency, lobulation, and dense, fibrous, grayish-white capsule are characteristic findings of parathyroid cancer. On microscopic histopathological analysis, dense fibrous trabeculae, mitoses, and capsular invasions are characteristic findings of parathyroid cancer. The etiology of parathyroid cancer is unknown. Parathyroid cancer must be differentiated from renal disease, immobility, and thiazides adverse effect. The incidence of parathyroid cancer is approximately 0.015 per 100,000 individuals in United States. Parathyroid cancer affects men and women equally. Common risk factors in the development of parathyroid cancer are multiple endocrine neoplasia type 1, hyperparathyroidism, and familial isolated hyperparathyroidism. The hallmark of parathyroid cancer is neck mass. A positive history of multiple endocrine neoplasiab type I, hyperparathyroidism, and previous radiation therapy to the head or neck is suggestive of parathyroid cancer. The most common symptoms of parathyroid cancer include weight loss, muscle weakness, fractures, constipation, fatigue, and bone pain. Patients with parathyroid cancer usually appear well. Physical examination of patients with parathyroid cancer is usually remarkable for lymphadenopathy and a palpable lump in the neck. Neck CT scan may be diagnostic of parathyroid cancer. Laboratory findings consistent with the diagnosis of parathyroid cancer include elevated serum calcium and serum parathyroid hormone. Findings on CT suggestive of parathyroid cancer include metastasis and invasion of surrounding tissues. The predominant therapy for parathyroid cancer is surgical resection. Adjunctive supportive therapy, chemotherapy, and radiation may be required. Supportive therapy for parathyroid cancer includes IV fluids, diuretics, and calcimimetic agents. Surgery is the mainstay of treatment for parathyroid cancer. There are no primary preventive measures available for parathyroid cancer. Secondary prevention strategy recommended following parathyroid cancer is germline DNA analysis for HRPT2/CDC73.

Historical Perspective

Parathyroid cancer was first described by Sainton and Millot, in 1933. In 1928, the first parathyroidectomy operation was conducted by Isaac Y. Olch to treat parathyroid lesions.

Pathophysiology

On gross pathology, stony-hard consistency, lobulation, and dense, fibrous, grayish-white capsule are characteristic findings of parathyroid cancer. On microscopic histopathological analysis, dense fibrous trabeculae, mitoses, and capsular invasions are characteristic findings of parathyroid cancer.

Causes

The etiology of parathyroid carcinoma is unknown.

Differential Diagnosis

Parathyroid cancer must be differentiated from renal disease, immobility, and thiazide adverse effect.

Epidemiology and Demographics

The incidence of parathyroid cancer is approximately 0.015 per 100,000 individuals in United States. Parathyroid cancer affects males and females equally.

Risk Factors

Common risk factors in the development of parathyroid cancer are multiple endocrine neoplasia type 1, hyperparathyroidism, and familial isolated hyperparathyroidism.

Natural history, Complications and Prognosis

Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as good. Common complications of parathyroid cancer include hypercalcemia, metastasis, and death.

Diagnostic Criteria

The diagnosis of parathyroid cancer is made when if any of the following 5 diagnostic criteria are met: Hypercalcemia greater than 14 milligrams per deciliter, serum parathyroid hormone levels greater than twice that of normal, a palpable cervical mass in a hypercalcemic patient, unilateral vocal cord paralysis with hypercalcemia, and concomitant renal and skeletal disease observed in a patient with a markedly elevated serum parathyroid hormone.

Staging

The staging of parathyroid cancer is based on whether there is localized or metastatic disease.

History and Symptoms

The hallmark of parathyroid cancer is a neck mass. A positive history of multiple endocrine neoplasia type I, hyperparathyroidism, and previous radiation therapy to the head or neck is suggestive of parathyroid cancer. The most common symptoms of parathyroid cancer include weight loss, muscle weakness, fractures, constipation, fatigue, and bone pain.

Physical Examination

Patients with parathyroid cancer usually appear well. Physical examination of patients with parathyroid cancer is usually remarkable for lymphadenopathy and palpable lump in the neck.

Laboratory Findings

Laboratory findings consistent with the diagnosis of parathyroid cancer include elevated serum calcium and serum parathyroid hormone.

Chest Xray

On chest x-ray, parathyroid cancer is characterized by metastases into lungs and bones.

CT

Neck CT scan may be diagnostic of parathyroid cancer.

MRI

MRI scan may be diagnostic of parathyroid cancer. Findings on MRI suggestive of parathyroid cancer include metastasis and invasion of surrounding tissues.

Echocardiography or Ultrasound

Neck ultrasound may be helpful in the diagnosis of parathyroid cancer. Findings on neck ultrasound suggestive of parathyroid cancer include structural irregularities of parathyroid gland and invasion of the surrounding tissues.

Other Imaging Findings

Other imaging studies for parathyroid cancer include sestamibi scan, venous sampling, or PET scan.

Medical Therapy

The predominant therapy for parathyroid cancer is surgical resection. Adjunctive supportive therapy, chemotherapy, and radiation may be required. Supportive therapy for parathyroid cancer includes IV fluids, diuretics, and calcimimetic agents.

Surgery

Surgery is the mainstay of treatment for parathyroid cancer.

Primary Prevention

There are no primary preventive measures available for parathyroid cancer.

Secondary Prevention

Secondary prevention strategy recommended following parathyroid cancer is germline DNA analysis for HRPT2/CDC73.

Reference